Holen Sie sich die Stockscreener-App
7.37
6.94%
-0.55
Handel nachbörslich:
7.59
0.22
+2.99%
Schlusskurs vom Vortag:
$7.92
Offen:
$7.77
24-Stunden-Volumen:
37,985
Relative Volume:
1.32
Marktkapitalisierung:
$12.12M
Einnahmen:
$1.47M
Nettoeinkommen (Verlust:
$-97.61M
KGV:
-4.9463
EPS:
-1.49
Netto-Cashflow:
$-80.90M
1W Leistung:
-2.90%
1M Leistung:
+17.17%
6M Leistung:
+38.66%
1J Leistung:
-33.75%
1-Tages-Spanne:
$7.00
$7.77
1-Wochen-Bereich:
$7.00
$8.09
52-Wochen-Spanne:
$3.8101
$37.50
Lyra Therapeutics Inc Stock (LYRA) Company Profile
Firmenname
Lyra Therapeutics Inc
Sektor
Branche
Telefon
617-373-4600
Adresse
480 ARSENAL WAY, WATERTOWN, MA
Vergleichen Sie LYRA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LYRA
Lyra Therapeutics Inc
|
7.37 | 13.02M | 1.47M | -97.61M | -80.90M | -1.49 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Lyra Therapeutics Inc Stock (LYRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-05-07 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-05-07 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-05-07 | Herabstufung | Jefferies | Buy → Hold |
| 2024-05-06 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-10-06 | Fortgesetzt | BTIG Research | Buy |
| 2023-08-31 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-05-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-05-26 | Eingeleitet | BTIG Research | Buy |
| 2020-05-26 | Eingeleitet | BofA/Merrill | Buy |
| 2020-05-26 | Eingeleitet | Jefferies | Buy |
| 2020-05-26 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Lyra Therapeutics Inc Aktie (LYRA) Neueste Nachrichten
Short interest data insights for Lyra Therapeutics Inc.Quarterly Portfolio Review & Verified Momentum Watchlists - newser.com
What valuation multiples suggest for Lyra Therapeutics Inc. stock2025 Key Highlights & Risk Controlled Stock Alerts - newser.com
Using data models to predict Lyra Therapeutics Inc. stock movementTreasury Yields & Daily Oversold Stock Bounce Ideas - newser.com
Regression analysis insights on Lyra Therapeutics Inc. performanceWeekly Market Report & Safe Capital Growth Tips - newser.com
Published on: 2025-10-09 05:19:19 - newser.com
Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study - Sahm
Lyra Therapeutics To Conduct One More Trial For Chronic Rhinosinusitis Treatment Candidate - Stocktwits
Lyra Therapeutics Announces Clinical Plan for LYR-210 and - GlobeNewswire
Lyra Therapeutics outlines path to NDA for CRS treatment - Investing.com
Lyra Therapeutics (LYRA) Advances CRS Treatment with Positive Tr - GuruFocus
Lyra Therapeutics outlines path to NDA for CRS treatment By Investing.com - Investing.com Australia
Lyra unveils clinical plan for LYR-210, to present late-stage sinusitis trial data - MarketScreener
Lyra Therapeutics Announces Clinical Plan for LYR-210 Following Positive ENLIGHTEN 2 Results and Upcoming FDA Engagement - Quiver Quantitative
Lyra Therapeutics, Inc. Announces Clinical Plan for Lyr-210 and Late-Breaking Oral Presentation of Phase 3 Enlighten 2 Study - MarketScreener
Multi asset correlation models including Lyra Therapeutics Inc.Weekly Profit Analysis & AI Powered Market Entry Strategies - newser.com
What the charts say about Lyra Therapeutics Inc. todayJuly 2025 Selloffs & Intraday High Probability Setup Alerts - newser.com
Using Python tools to backtest Lyra Therapeutics Inc. strategiesMarket Volume Summary & Real-Time Volume Triggers - newser.com
Is Lyra Therapeutics Inc. stock supported by strong cash flowsLayoff News & Free Weekly Chart Analysis and Trade Guides - newser.com
What analysts say about Lyra Therapeutics Inc stockRisk Adjusted Returns & Free Stock Price Trend Analysis - earlytimes.in
Is Lyra Therapeutics Inc. stock ready for a breakoutPrice Action & Growth Focused Investment Plans - newser.com
Goldman Sachs Group Inc. Sells 185,314 Shares of Lyra Therapeutics, Inc. $LYRA - Defense World
Lyra Therapeutics (NASDAQ:LYRA) Stock Price Up 0.5% – Here’s Why - Defense World
Is Lyra Therapeutics Inc a good long term investmentUtilities Sector Analysis & Target Triple-Digit Stock Opportunities - earlytimes.in
What drives Lyra Therapeutics Inc stock priceEarnings Miss Alerts & Capital Allocation Recommendations - earlytimes.in
US Market Recap: How much upside does Lyra Therapeutics Inc haveGDP Growth & Trade Opportunity Analysis - خودرو بانک
Tech Rally: Is Lyra Therapeutics Inc stock a good pick for beginnersMarket Performance Report & Verified Technical Signals - khodrobank.com
Quantitative breakdown of Lyra Therapeutics Inc. recent moveJuly 2025 Closing Moves & High Accuracy Swing Entry Alerts - newser.com
Market Moves: Should I hold or sell Lyra Therapeutics Inc nowEarnings Summary Report & Low Risk High Reward Trade Ideas - خودرو بانک
Live market analysis of Lyra Therapeutics Inc.July 2025 Earnings & Risk Adjusted Buy and Sell Alerts - newser.com
Top chart patterns to watch in Lyra Therapeutics Inc.IPO Watch & Safe Capital Growth Trade Ideas - newser.com
Can swing trading help recover from Lyra Therapeutics Inc. lossesBull Run & Technical Entry and Exit Alerts - newser.com
Is Lyra Therapeutics Inc. a candidate for recovery playJuly 2025 Trends & Weekly Setup with ROI Potential - newser.com
Travel Stocks: Will Lyra Therapeutics Inc. face regulatory challenges2025 Volume Leaders & Fast Exit and Entry Strategy Plans - خودرو بانک
Macro Review: Why is AGNCL stock going up2025 Dividend Review & Fast Gain Swing Alerts - خودرو بانک
Finanzdaten der Lyra Therapeutics Inc-Aktie (LYRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Lyra Therapeutics Inc-Aktie (LYRA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Cavalier Jason | Chief Financial Officer |
Jul 10 '25 |
Sale |
8.91 |
684 |
6,094 |
519,316 |
5.15%
1.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):